Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Redirected, genetically-engineered T regulatory cells and their use in suppression of autoimmune and inflammatory disease

Redirected, genetically-engineered T regulatory cells and their use in suppression of autoimmune and inflammatory disease

US Patent 11326147 · Granted May 10, 2022

Estimated economic value: $30,615,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Microbiome-based diagnosis, prediction and treatment of relapsing obesity2024
T-cells comprising two different chimeric antigen receptors and uses thereof2024
Method and apparatus for predicting response to food2024
T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses 2024
Methods of culturing t cells and uses of same2024
Method and apparatus for predicting response to food2023
Method and apparatus for predicting response to food2021
Methods for treating psoriasis2020
Method and apparatus for predicting response to food2019
Immunotherapy using redirected allogeneic cells2017
Methods for modulating Th1/Th2 cell balance by increasing leptin activity2016
Anti-inflammatory peptides and use thereof2016